6O0M

crystal structure of BCL-2 F104L mutation with venetoclax

Summary for 6O0M

Entry DOI	10.2210/pdb6o0m/pdb
Descriptor	Apoptosis regulator Bcl-2,Bcl-2-like protein 1,Apoptosis regulator Bcl-2, 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl )methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide, DI(HYDROXYETHYL)ETHER, ... (4 entities in total)
Functional Keywords	bcl-2, venetoclax, complex, protein-protein interface inhibitor, resistance mutation, fda approved drug complex, apoptosis
Biological source	Homo sapiens (Human) More
Total number of polymer chains	1
Total formula weight	20616.46
Authors	Birkinshaw, R.W.,Luo, C.S.,Colman, P.M.,Czabotar, P.E. (deposition date: 2019-02-16, release date: 2019-05-22, Last modification date: 2023-10-11)
Primary citation	Birkinshaw, R.W.,Gong, J.N.,Luo, C.S.,Lio, D.,White, C.A.,Anderson, M.A.,Blombery, P.,Lessene, G.,Majewski, I.J.,Thijssen, R.,Roberts, A.W.,Huang, D.C.S.,Colman, P.M.,Czabotar, P.E. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nat Commun, 10:2385-2385, 2019 Cited by PubMed: 31160589 DOI: 10.1038/s41467-019-10363-1 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.75 Å)

Structure validation